Scientific Program
ATTD is the leading international meeting point where clinicians, diabetes care providers, researchers, industries, investors, reimbursement authorities, and people with diabetes, assemble with the aim to be share knowledge and develop collaborations.
Presentations and discussions will be given by many distinguished professionals in the field and will include topics such as digital clinics, decision support systems/advisors, big data and artificial intelligence based decision support systems, glucose sensors, closed-and open-loop systems, artificial pancreas, devices for diabetic prevention, new insulins and new medications, insulin pumps and many more.
List of Confirmed Titles and Speakers*
| Ananta | Addala | USA | The role of perceived discrimination in diabetes disparities: Experience of underrepresented individuals |
| Peter | Adolfsson | Sweden | How are data being integrated into EHRs |
| Usage of smart pens in pediatric population | |||
| Halis | Akturk | USA | The role of CGM in early detection of Immune checkpoint inhibitor (Cancer immunotherapy) induced type 1 diabetes |
| Stephanie | Amiel | UK | CLEAR and HARPdoc – new learning from studies in impaired hypoglycaemia awareness |
| Robert | Andrews | UK | CGM in non-diabetic hypoglycaemia (insulinoma, post-bariatric / reactive) |
| Lia | Bally | UK | Beyond glycemia: addressing overweight and obesity in type 1 diabetes |
| Katharine | Barnard-Kelly | UK | Impact of screening and understanding the risk |
| Improving glycemic control and reducing diabetes distress: a 2-way street | |||
| Roy | Beck | USA | Afrezza use in pediatrics – INHALE 1 study |
| Richard | Bergenstal | UK | Adapting CGM Reports for the use in Real Life |
| DEBATE: HbA1c and not CGM should be the gold standard to evaluate glucose control – CON | |||
| Mithun | Bhartia | India | Together with Manoj Chawla – A Duologue on CGM in non-reimbursable markets |
| Riccardo | Bonfanti | Italy | The role of technology in monitoring and managing presymptomatic (stage 1&2) type 1 diabetes in children following screening |
| Emanuele | Bosi | Italy | Monitoring children with early type 1 diabetes: the Italian experience |
| Anne-Sophie | Brazeau | Canada | Food choices matter: The impact of dietary patterns on glucose control when using automated insulin delivery |
| Marc | Breton | USA | Fully automated closed loop based on artificial intelligence |
| Adrian | Brown | UK | Essential nutrition support for GLP-1/GIP therapy success |
| Giacomo | Cappon | Italy | Combining digital twins and LLMs for advanced personalized insulin therapy in type1 diabetes |
| Per-Ola | Carlsson | Sweden | Hypoimmune pancreatic islet transplantation in type 1 diabetes |
| Eda | Cengiz | USA | Shifting the paradigm: Innovations in gender-specific diabetes technology |
| Manoj | Chawla | India | Together with Minhun Bhratia – A Duologue on CGM in non-reimbursable markets |
| Pratik | Choudhary | UK | CGM use in clinical trials |
| Iain | Cranston | UK | Data standards and data ownership for device interoperability: The NHSE / PRSB experience & debate |
| Tali | Cukierman-Yaffe | Israel | Practical guidance on use of AID in a heterogenous population of older adults with diabetes |
| Deniz | Dalton | USA | Helmsley funding areas and Type 1 Diabetes and eXercise Initiative (T1-DEXI) |
| Hans | De Vries | the Nathrlands | CGM in type 2 diabetes |
| Katy | Digovich | USA | Minutia: Leveraging our nanoparticle platform for safety and success with our minimally invasive sc-islet transplant |
| Klemen | Dovc | Slovenia | Is VO2max important for exercise planning |
| Robert | Eckel | USA | Coronary heart disease in T1D, is it different than in T2D |
| Dominic | Ehrmann | Germany | HCPs and Patients’ view on Smart Pens: Results of the dt-report 2025 |
| Anas | El Fathi | USA | A week of automated insulin delivery used to titrate basal insulin in type 2 diabetes |
| Chiara | Fabris | USA | Digital twins to improve glycemic management in females with type 1 diabetes |
| CGM metrics predicted microvascular diabetes complications | |||
| Andrea | Facchinetti | Italy | Advanced CGM/AI-based algorithms for diabetes |
| Gregory | Forlenza | USA | Is ultra-fast acting insulin improving AID – the evidence is mixed, but there is a catch |
| Jason | Gaglia | USA | Dendritic cells for treatment of type 1 diabetes |
| Robin L. | Gal | USA | Moving forward with exercise: Insulin and education strategies for glycemic management |
| Gerlandine | Gallen | UK | Beyond the Device: The Importance of Leadership and Mentorship for Diabetes Educators |
| Satish | Garg | USA | Ways to overcome challenges in GLP use in type 1 diabetes |
| CGM frequency use in type 2 diabetes | |||
| Nicole | Glaser | USA | ISPAD DKA guidelines – what is new? |
| Nicola | Guess | UK | CGM as a guide to lifestyle and weight management |
| Amit | Gupta | India | Benchmarking better: Using technology to align practice with evolving diabetes care guidelines |
| Ahmad | Haidar | Canada | Concurrent use of AID with SGLT-2 |
| Michael | Haller | USA | Screening programs for type 1 diabetes in the US: From research to standard of care |
| Lutz | Heinemann | Germany | Non-invasive glucose monitoring |
| Irl | Hirsch | USA | “I’ve run out of real estate”- why some patients struggle with insulin pump therapy |
| Understanding the etiology and best treatment strategies for obesity in type 1 diabetes | |||
| Korey | Hood | USA | Experience of being anti-body positive and choices available |
| William | Horton | USA | CGM-based prediction of cardiovascular outcomes in diabetes |
| Roman | Hovorka | UK | Comparing automated insulin delivery systems (AIDs): The good, the bad and the ugly |
| Sufyan | Hussain | UK | Lessons from open-source systems |
| Fasting during the night with hybrid Closed-loop | |||
| Concetta | Irace | Italy | Connected pens in type 2 diabetes |
| Johan` | Jendle | Sweden | The need for interoperability |
| Next generation of smart pens | |||
| Anna | Kahkoska | USA | Challenges of growing older with type 1 diabetes as a female |
| Jothydev | Kesavadev | India | Artificial Intelligence (AI) in diabetes care: Real-world EMR integration with DTMS and future directions |
| Partha | Kar | UK | Challenging industry or widening gaps in access to technology |
| Boris | Kovatchev | USA | Could CGM replace antibodies screening? |
| How AI can help the human-machine co-regulation of diabetes | |||
| The continuum between hybrid and fully-automated closed-loop | |||
| Yogish C. | Kudva | USA | Current evidence for use of AID systems in older adults with diabetes |
| Lori | Laffel | USA | Executive function and use of diabetes technologies |
| Rayhan | Lal | USA | Closed-loop systems: Future challenges and considerations |
| Janni | Larsson | Denmark | Diabetic retinopathy in relation to pregnancy |
| Alon | Liberman | Israel | The role of psychological interventions in promoting sustainable weight loss |
| Yu Kuei (Alex) | Lin | USA | Hypoglycemia risk in type 2 diabetes on CGM |
| David | Maahs | USA | Bridging the gap between population screening and immunotherapy |
| Targeting lower glucose levels in children with type 1 diabetes | |||
| Julia | Mader | Austria | Using apps to support management of type 2 diabetes |
| Clinical Evidence for Smart Pens | |||
| Thomas | Martens | USA | Technology implementation in primary care: what is the best model? |
| Chantal | Mathieu | Belgium | Experience of EDENTIFI clinical study |
| C-peptide: A marker for functional beta cell mass? | |||
| Shweta | Mital | Canada | Cost Effectiveness of Screening and Immune Interventions in type 1 diabetes |
| Viswanathan | Mohan | India | Subtypes of prediabetes |
| Dale | Morrison | Australia | Use of whey protein to reduce risk of hypoglycemia during exercise for people with type 1 diabetes |
| Medha | Munshi | USA | Challenges & barriers to use of AID systems in older adult patient and health care provider perspective |
| Helen | Murphy | UK | Pregnancy outcomes in early-onset type 2 diabetes |
| Revital | Nimri | Israel | Twenty-four-hour fasting with hybrid closed-loop |
| Kirsten | Nørgaard | Denmark | What are the physiological differences during exercise in type 1 diabetes compared to healthy individuals? |
| Graham | Ogle | Australia | Equity in Action: Lessons from the Global South in Delivering Diabetes Care for Children |
| Tal | Oron | Israel | Together with Moshe Phillip – Israeli Experience: ADIR – General population and families screening |
| Naushira | Pandya | USA | Challenges and opportunities of using technology in rehabilitation, nursing homes and assisted living settings |
| Rakesh | Parikh | India | Generative AI as patient education partner |
| Francisco J. | Pasquel | USA | Real-life data on GLP use in type 1 diabetes |
| Moshe | Phillip | Israel | Together withTal Oron – Israeli Experience: ADIR – General population and families screening |
| Tamar | Propper-Lewinsohn | Israel | Technology and disordered eating behavior in type 1 diabetes management |
| Wu | Qian | China | Randomized Trial of an Adaptive AI-Based VR Sports System for Adolescents at Risk of Type 2 Diabetes |
| Ivana | Rabbone | Italy | Long-term impact of early advanced technology adoption (CGM/AID) on hypoglycemia awareness and fear in children and families |
| Yves | Reznik | France | Automated insulin delivery in type 2 diabetes |
| Michael | Riddell | Canada | Lactate metabolism and why a continuous lactate monitor might be of value |
| Physical activity for Cardiometabolic risk reduction in type 1 diabetes | |||
| Teresa | Rodriguez-Calvo | Germany | Role of viruses in pathogenesis of type 1 diabetes |
| Martina | Rothenbühler | Switzerland | Interplay between the menstrual cycle and type 1 diabetes management |
| Holger | Russ | USA | Stem cell derived beta cells for cell therapy: Progress, hurdles and future directions |
| Banshi | Saboo | India | Showcasing area-side improvement in type 1 diabetes across India |
| Andrea | Scaramuzza | Italy | Frequency of diabetic ketoacidosis following pilot screening for type 1 diabetes in the general Italian population |
| Desmond | Schatz | USA | Is it time to re-evaluate our recommendations for screening the general population for risk for type 1 diabetes? |
| Oliver | Schnell | Germany | Targets and best therapies for blood pressure and cholesterol |
| Eleanor | Scott | UK | Expanding CGM use in GDM pregnancy |
| Jane Jeffrie | Seley | USA | “To wear or not to wear” integrating wearable technology into Adult Diabetes Care |
| Elizabeth | Selvin | USA | DEBATE: HbA1c and not CGM should be the gold standard to evaluate glucose control – PRO |
| Viral | Shah | USA | ADJUST T1D study – design and glycemic outcome |
| CGM for prediabetes | |||
| Devorah | Shapiro | Israel | How to help our children with diabetes choose the best diabetes technology for them? A tailored and personalized method |
| Jennifer | Sherr | USA | Optimizing AID systems: Strategies for enhanced glycemic control |
| Smadar | Shilo | Israel | CGM in individuals without diabetes |
| Alpana | Shukla | USA | Benefits of meal sequencing in a variety of populations: T1D, T2D and prediabetes |
| Jay | Skyler | USA | Challenges in the treatment of type 1 diabetes |
| Janet | Snell-Bergeon | USA | ADJUST T1D study – Cardiovascular outcomes |
| MERIT: Impact of menstruation on glycemic response and exercise in females with type 1 diabetes | |||
| Tim | Street | UK | AI for Carb Counting and Insulin Dosing: How not to do it |
| Jannet | Svensson | Denmark | Adhesives from pumps and sensors: how to best address allergy and inflammation |
| Martin | Tauschmann | Austria | Continuous Glucose Monitoring (CGM) accuracy – balancing access, cost and safety |
| Maria | Vasiloglou | Switzerland | Evidence-based apps that improve nutrition and diabetes outcome |
| Josep | Vehi | Spain | Glycemic control with AI & ML: Lessons learned and next steps |
| Piotr | Witkowski | USA | Optimizing Immunomodulation to Improve Outcomes of Beta Cell Replacement Therapy in Patients with T1DM |
| Yariv | Yogev | Israel | What is new in pregnancy complicated by diabetes |
| Dessi | Zaharieva | USA | Type 1 diabetes and exercise education & information resources, upcoming innovative solutions, and INSPIRE-T1D |
| Exercise and TYPE 1 DIABETES: Clinical trials versus real-world evidence – which tells the full story? |
*List of Confirmed Titles and Speakers as of 22 October, 2025